Free Trial

Jazz Pharmaceuticals (JAZZ) Competitors

Jazz Pharmaceuticals logo
$108.07 +0.25 (+0.23%)
Closing price 04:00 PM Eastern
Extended Trading
$112.58 +4.51 (+4.17%)
As of 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

JAZZ vs. RPRX, CORT, PRGO, SUPN, PCRX, OMER, NKTR, ASMB, CPIX, and LLY

Should you be buying Jazz Pharmaceuticals stock or one of its competitors? The main competitors of Jazz Pharmaceuticals include Royalty Pharma (RPRX), Corcept Therapeutics (CORT), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceuticals" industry.

Jazz Pharmaceuticals vs.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Jazz Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.

Royalty Pharma has a net margin of 37.94% compared to Jazz Pharmaceuticals' net margin of 11.60%. Jazz Pharmaceuticals' return on equity of 29.30% beat Royalty Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals11.60% 29.30% 9.72%
Royalty Pharma 37.94%24.40%14.01%

In the previous week, Jazz Pharmaceuticals had 5 more articles in the media than Royalty Pharma. MarketBeat recorded 21 mentions for Jazz Pharmaceuticals and 16 mentions for Royalty Pharma. Jazz Pharmaceuticals' average media sentiment score of 1.38 beat Royalty Pharma's score of 1.12 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jazz Pharmaceuticals
17 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Royalty Pharma
10 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are owned by institutional investors. 4.2% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 18.9% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Royalty Pharma has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$4.06B1.65$414.83M$7.5014.49
Royalty Pharma$2.26B8.24$858.98M$1.8517.49

Jazz Pharmaceuticals currently has a consensus price target of $182.79, indicating a potential upside of 68.14%. Royalty Pharma has a consensus price target of $42.50, indicating a potential upside of 31.32%. Given Jazz Pharmaceuticals' higher probable upside, research analysts clearly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93
Royalty Pharma
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00

Jazz Pharmaceuticals received 816 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 80.83% of users gave Jazz Pharmaceuticals an outperform vote while only 67.98% of users gave Royalty Pharma an outperform vote.

CompanyUnderperformOutperform
Jazz PharmaceuticalsOutperform Votes
1143
80.83%
Underperform Votes
271
19.17%
Royalty PharmaOutperform Votes
327
67.98%
Underperform Votes
154
32.02%

Summary

Jazz Pharmaceuticals beats Royalty Pharma on 10 of the 19 factors compared between the two stocks.

Get Jazz Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JAZZ vs. The Competition

MetricJazz PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.69B$6.47B$5.31B$8.31B
Dividend YieldN/A2.64%5.20%4.10%
P/E Ratio15.298.5926.6919.58
Price / Sales1.65257.78393.58120.51
Price / Cash4.9165.8538.2534.62
Price / Book1.836.396.744.47
Net Income$414.83M$143.98M$3.23B$248.32M
7 Day Performance-0.25%-0.06%0.01%-1.26%
1 Month Performance4.34%1.64%8.69%10.52%
1 Year Performance4.59%-0.73%18.36%8.53%

Jazz Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JAZZ
Jazz Pharmaceuticals
4.9103 of 5 stars
$108.07
+0.2%
$182.79
+69.1%
+2.2%$6.66B$4.06B15.223,200Positive News
RPRX
Royalty Pharma
4.7545 of 5 stars
$34.25
+0.7%
$42.50
+24.1%
+18.2%$19.74B$2.26B23.6280News Coverage
Positive News
Analyst Downgrade
CORT
Corcept Therapeutics
4.5087 of 5 stars
$74.82
-0.3%
$138.25
+84.8%
+165.9%$7.93B$685.45M59.38300Insider Trade
PRGO
Perrigo
4.8753 of 5 stars
$27.20
+0.6%
$33.00
+21.3%
-10.0%$3.74B$4.34B-23.258,900Positive News
SUPN
Supernus Pharmaceuticals
2.6266 of 5 stars
$33.05
-1.1%
$36.00
+8.9%
+15.0%$1.85B$668.00M30.89580Positive News
PCRX
Pacira BioSciences
1.9819 of 5 stars
$26.15
+1.1%
$26.44
+1.1%
-15.1%$1.21B$702.77M-12.88720Positive News
OMER
Omeros
3.9179 of 5 stars
$3.32
+3.1%
$22.50
+577.7%
-5.8%$193.58MN/A-1.44210Analyst Revision
Gap Down
High Trading Volume
NKTR
Nektar Therapeutics
4.1469 of 5 stars
$0.70
+1.5%
$4.50
+547.5%
-62.3%$129.34M$87.25M-0.83220Gap Down
ASMB
Assembly Biosciences
3.9862 of 5 stars
$13.80
+2.8%
$33.00
+139.1%
-10.4%$105.40M$32.15M-2.22100
CPIX
Cumberland Pharmaceuticals
0.6116 of 5 stars
$5.45
+15.7%
N/A+230.5%$81.54M$41.08M-7.0880Gap Up
LLY
Eli Lilly and Company
4.9734 of 5 stars
$754.95
-0.3%
$1,011.37
+34.0%
-11.0%$715.49B$49.00B64.4739,000Trending News

Related Companies and Tools


This page (NASDAQ:JAZZ) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners